Edition:
United States

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

77.30EUR
11:35am EDT
Change (% chg)

€-1.34 (-1.70%)
Prev Close
€78.64
Open
€79.00
Day's High
€79.30
Day's Low
€76.80
Volume
459,544
Avg. Vol
467,264
52-wk High
€98.82
52-wk Low
€61.88

Select another date:

Thu, Apr 19 2018

BRIEF-Galapagos NV Creates New Warrant Plan

* BOARD OF DIRECTORS CREATED 1.6 MILLION WARRANTS UNDER NEW WARRANT PLANS

BRIEF-Galapagos Announces ISABELA Phase 3 Program In IPF

* ANNOUNCES THE DESIGN OF A WORLDWIDE PHASE 3 PROGRAM, TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

BRIEF-Galapagos Announces Isabela Phase 3 Program In IPF

* ANNOUNCES DESIGN OF A WORLDWIDE PHASE 3 PROGRAM TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

BRIEF-Galapagos FY Net Result Swings To Loss Of 115.7 Million Euros

* REPORTED ON THURSDAY FY NET LOSS OF €115.7 MILLION, COMPARED TO NET PROFIT OF €54.0 MILLION IN 2016

BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106

* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT

BRIEF-Galapagos And MorphoSys Present Results From Phase 1 Study With MOR106 In Atopic Dermatitis

* GALAPAGOS AND MORPHOSYS ANNOUNCED ON SATURDAY THAT MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS (AD) PATIENTS

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

BRIEF-Galapagos Reports Preliminary Topline Results In Osteoarthritis Study

* REPORTED ON SUNDAY, POSITIVE PRELIMINARY TOPLINE RESULTS WITH A PHASE 1B STUDY IN OSTEOARTHRITIS (OA) PATIENTS IN THE UNITED STATES

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

BRIEF-Galapagos To Enter NASDAQ Biotech Index Effective Dec 18‍​

* TO ENTER NASDAQ BIOTECH INDEX EFFECTIVE DEC 18‍​ Source text: http://bit.ly/2jM5AGV Further company coverage: (Gdynia Newsroom)

Select another date: